Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …

Mutations in the KRAS oncogene are dominant features in pancreatic ductal
adenocarcinoma (PDA). Because KRAS itself is considered “undruggable,” targeting …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, metastatic disease with
limited treatment options. Factors contributing to the metastatic predisposition and therapy …

Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic
cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving …

Purpose: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and
PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has …

KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an
intractable pharmacologic target. Consequently, defining RAS effector pathway (s) required …

Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal
adenocarcinoma (PDAC) and the key drivers of its initiation and progression. Longstanding …

Over 90% of pancreatic cancers present mutations in KRAS, one of the most common
oncogenic drivers overall. Currently, most KRAS mutant isoforms cannot be targeted directly …

Our increasing knowledge of the mechanisms behind the progression of pancreatic cancer
(PC) has not yet translated into effective treatments. Many promising drugs have failed in the …

Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal
adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options …